Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Deals & Financings

VC fundings, mergers and acquisitions, and other financing events...

Hong Kong's Aptorum Stages $12 Million US IPO for Drug Development
VoxelCloud Raises $50 Million for AI-based Clinical Decision Support
Innovent Forms Three-Drug $391.5 Million Collaboration with Incyte
I-Mab Out-Licenses Rights for Diabetes Drug to CSPC for $22 Million
WuXi AppTec Completes Hong Kong IPO; Finishes First Trading Session Unchanged
Upcoming event
San Francisco, USA
January 6, 2019
Use 'ChinaBio200' to get a USD200 Discount!
Shanghai , China
May 8-9, 2019
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China